Meclofenamate treatment of recurrent idiopathic nephrotic syndrome with focal segmental glomerulosclerosis after renal transplantation.
Recurrent corticosteroid-resistant nephrotic syndrome with focal segmental glomerulosclerosis (FSGS) caused the failure of a first renal allograft in a 41-year-old man. Recurrence of the nephrotic syndrome in the second renal allograft was successfully controlled by the administration of meclofenamate, and the renal function has remained stable for 2 1/2 years. No accepted treatment is available for corticosteroid-resistant nephrotic syndrome with FSGS. This report suggests that administration of meclofenamate might be beneficial in some patients with corticosteroid-resistant nephrotic syndrome and FSGS. Because of the potential side effects, however, careful supervision of this therapy is of the utmost importance.
D000328:Adult; D003404:Creatinine / Q000097:blood; D005921:Glomerulonephritis / Q000188:drug therapy*; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008469:Meclofenamic Acid / Q000627:therapeutic use*; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000209:etiology; D011183:Postoperative Complications / Q000188:drug therapy; D011507:Proteinuria / Q000188:drug therapy / Q000209:etiology; D012008:Recurrence; D062367:ortho-Aminobenzoates / Q000627:therapeutic use*
D062367:ortho-Aminobenzoates; D008469:Meclofenamic Acid; D003404:Creatinine